Anubala, B (2017) Clinical evaluation of Sirupulladi Ennai (a siddha drug) for the treatment of Neerkana Mantham (URI) in children. Masters thesis, National Institute of Siddha, Chennai.
|
Text
320418317anubala.pdf Download (2MB) | Preview |
Abstract
The literature evidence of both the siddha and modern literatures were reviewed and the reviews and recent studies on the individual drugs of the trial drug were collected. Patients attending the OPD and IPD of NIS having the complaints of NEERKANA MANTHAM are diagnosed clinically. Sirupulladi Ennai was selected as the drug for the management of NEERKANA MANTHAM. The study is conducted after the proposal was screened by the Screening committee of National Institute of Siddha. The Clinical study has been approved by IEC of NIS. The trial is registered in Clinical trial Registry of India. The Authentication of ingredients of the trial drug was done obtained from Medicinal Botanist NIS. The trial drugs were prepared by the author in the Gunapadam practical laboratory of National Institute of Siddha, after getting proper authentication of raw drugs from the Medicinal botany department at NIS. The trial drug was prepared by the standard operating procedure as mentioned in the protocol. The drug is found to have with good anti inflammatory activity. The physicochemical analysis reveals high saponification value, Good refractive index and total Ash value is limited, low moisture content. Phyto chemical Analysis has been carried out in the trail drug Sirupulladi Ennai and it is found that the presence of flavonoids, steroids, coumarins, phenols, saponins and proteins are found to be positive and the presence of alkaloids, glycosides, sugar, triterepnoids, tannins and anthocyanin are found to be negative. The Bio chemical analysis of trial medicine showed the presence of Sulphate, and Chloride. The patients have not complained of any adverse effects or difficulties during the course of treatment. Thus the drug is found to be safe and effective in the management of neerkana mantham. The observations made during the clinical study showed that the trail drug sirupulladi ennai was clinically effective. CONCLUSION: The Siddha system of medicines has certainity with safer medications to treat children. In the present study, the trial drug sirupulladi ennai is used for the treatment of children of age group, 3-7 years who are all diagnosed to have neerkanamantham. The ingredients of sirupulladi ennai are feasible and useful. These may serve as potentially a useful drug at a lower cost since most of them had anti-inflammatory activity and the physicochemical analysis reveals high saponification value, Good refractive index and total Ash value is limited, low moisture content. Phyto chemical Analysis has been carried out in the trail drug Sirupulladi Ennai and it is found that the presence of flavonoids, steroids, coumarins, phenols, saponins and proteins are found to be positive. The Bio chemical analysis of trial medicine showed the presence of Sulphate, and Chloride. Clinical results were found to be significant. Good improvement was found in 65% of the cases, moderately in 25% of cases and mildly in 10% of cases. The present clinical study has established that sirupulladi ennai is having good result in reducing the majority of the symptoms of neerkanamantham. This in turn, provided a further research and opportunity for new drug established in the management of neerkanamantham. By encouraging results of above study the drug may be taken for larger study in treatment of neerkana mantham.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | (Reg.No: 321414202) |
| Uncontrolled Keywords: | Sirupulladi Ennai ; siddha drug ; treatment ; Neerkana Mantham ; upper respiratory tract infection (URI) ; children ; Clinical study. |
| Subjects: | AYUSH > Kuzhanthai Maruthuvam |
| Depositing User: | Kambaraman B |
| Date Deposited: | 24 Sep 2018 02:20 |
| Last Modified: | 24 Sep 2018 02:21 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/9605 |
Actions (login required)
 |
View Item |
